Reneo Pharmaceuticals Stock Cash Per Share
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Reneo Pharmaceuticals fundamentals help investors to digest information that contributes to Reneo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reneo Stock. The fundamental analysis module provides a way to measure Reneo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reneo Pharmaceuticals stock.
Reneo |
Reneo Pharmaceuticals Company Cash Per Share Analysis
Reneo Pharmaceuticals' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Reneo Pharmaceuticals Cash Per Share | 5.18 X |
Most of Reneo Pharmaceuticals' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reneo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Reneo Pharmaceuticals has a Cash Per Share of 5.18 times. This is 19.08% higher than that of the Biotechnology sector and 19.63% higher than that of the Health Care industry. The cash per share for all United States stocks is 3.39% lower than that of the firm.
Reneo Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reneo Pharmaceuticals' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reneo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reneo Pharmaceuticals by comparing valuation metrics of similar companies.Reneo Pharmaceuticals is currently under evaluation in cash per share category among its peers.
Reneo Fundamentals
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Shares Owned By Insiders | 5.19 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 3.4 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Net Income | (77.39 M) | |||
| Cash And Equivalents | 126.85 M | |||
| Cash Per Share | 5.18 X | |||
| Total Debt | 973 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 15.84 X | |||
| Book Value Per Share | 2.30 X | |||
| Cash Flow From Operations | (63.68 M) | |||
| Short Ratio | 27.39 X | |||
| Earnings Per Share | (16.80) X | |||
| Target Price | 2.25 | |||
| Beta | 0.22 | |||
| Market Capitalization | 6.08 M | |||
| Total Asset | 107.44 M | |||
| Retained Earnings | (218.47 M) | |||
| Working Capital | 88.44 M | |||
| Net Asset | 107.44 M |
About Reneo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reneo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reneo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reneo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |